HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Counts On OTC Switches Adding $1bn In Consumer Revenues By 2026

Executive Summary

Sanofi eyes $1bn top line growth from OTC switches of ED drug Cialis and flu drug Tamiflu after they launch by 2026, says CEO Paul Hudson. Like switch consultants, though, he acknowledges the high bar for approval moving additional Rx ingredients to OTC.

You may also be interested in...



Sanofi To Divest 60% Of Brands In Consumer Healthcare Overhaul

Sanofi will look to offload around 150 OTC brands as part of a radical overhaul of its Consumer Healthcare operation. The new head of the business Julie Van Ongevalle has unveiled a wide-ranging turnaround plan with the goal of transforming Sanofi into the OTC market leader.

Viagra Connect To Launch In Ireland Following Rx-to-OTC Switch

Viagra will soon be available OTC in Ireland following a successful switch, but patients will have to complete a mandatory consultation with a pharmacist before the ED treatment can be supplied.

Sanofi Benefits From Stockpiling In Q1, Predicts Long-Term Uplift In Supplements Demand

Sanofi benefits from coronavirus-triggered stockpiling in Q1, with Consumer Healthcare head Alan Main suggesting the pandemic may have turned more consumers into regular dietary supplement users

Related Content

Topics

UsernamePublicRestriction

Register

RS149515

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel